1. At a Glance – The “Syrup, Cream & Debt” Story Nobody Warned You About
Zenith Drugs Ltd is that classic SME pharma stock that looks disciplined on the outside, WHO-GMP certified on LinkedIn, and slightly chaotic once you open the financials like an auditor opening a dusty Godrej almirah. Incorporated in 2000, listed in Feb 2024, current price hovering around ₹52, market cap roughly ₹89 Cr, and a P/E of ~21, this is a company that manufactures everything from oral powders to injectables, while simultaneously manufacturing working capital stress with equal dedication.
Latest half-year sales (H1 FY26) clocked in at ₹78 Cr, which looks healthy until you notice that PAT decided to fall down the stairs by ~55% YoY. Debt is sitting at ~₹52 Cr, ROCE is 12.9%, ROE is 11.1%, and debtor days are chilling at 167 days like they’re on paid leave. Promoters still hold ~70%, no pledging, but CFOs are resigning faster than interns during audit season.
So the big question before we go further: is Zenith Drugs a boring government-supply pharma compounder going through a temporary indigestion, or is this one of those “tender-driven adrenaline stocks” where numbers look great only when the tender gods are happy?
2. Introduction – Welcome to the Government Tender Olympics
Zenith Drugs doesn’t scream innovation. It doesn’t whisper breakthrough molecules. It politely clears its throat and says, “ORS sachet chahiye kya?”
This is a company built around volume, tenders, institutional orders, and third-party manufacturing. If Indian pharma had a middle-class neighbourhood, Zenith Drugs would be the reliable medical store uncle who sells everything from cough syrup to ointment and always gives change correctly.
But reliability in business doesn’t always translate to elegance in financials. Zenith has grown sales at a decent clip over the last few years, but profitability has mood swings sharper than a commodity trader on expiry day. FY24 PAT was ₹10 Cr, TTM PAT has collapsed to ~₹4 Cr, and the latest half-year numbers show margin compression thanks to higher costs, interest, depreciation, and tax volatility.
The IPO story was simple: raise ~₹40.7 Cr, expand capacity, upgrade manufacturing, fund working capital, and scale up. Reality? Capex happened, debt also happened, and cash flows… well… decided to take a long tea break.
So before you romanticize “pharma SME + government tenders,” remember: this sector rewards execution but brutally punishes sloppy working capital discipline. Ready to dissect? Let’s go.
3. Business Model – WTF Do They Even Do?
Zenith Drugs is a formulation-focused pharma manufacturer with a buffet-style product portfolio. No APIs, no fancy biologics, no CRISPR drama. Just good old formulations.
They manufacture and trade:
- Oral powders (ORS is their local celebrity product)
- Liquid orals (syrups galore)
- Liquid externals
- Ointments & creams (their biggest revenue contributor)
- Tablets, capsules, injections
The company operates a WHO-GMP certified manufacturing facility in Indore, producing 250+ molecules and ~780 SKUs. This is not a “one-product risk” company; it’s more like a pharma kirana store with scale.
Revenue comes from four main channels:
- Branded generic marketing
- Third-party job work manufacturing
- Government & institutional tenders
- Exports via merchant dealers (small but present)
Geographically, Zenith sells across 18+ Indian states and exports to places like Cambodia, Myanmar, Yemen, Bhutan, and parts of Africa. No USFDA or EU dominance here — this is pure emerging market + government supply hustle.
Key clients include Ajanta Pharma, Micro Labs, Troikaa, May & Baker
